- Home
- CALC vs HHS Comparison
CALC vs HHS Comparison
Compare CALC & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CALC | HHS |
|---|---|---|
| Founded | 2011 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 22.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CALC | HHS |
|---|---|---|
| Price | $5.40 | $3.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 96.2K | 10.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $166,841,000.00 |
| Revenue This Year | N/A | $6.54 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $2.33 |
| 52 Week High | $7.20 | $5.54 |
Technical Indicators
Market Signals| Indicator | CALC | HHS |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 50.28 |
| Support Level | $5.05 | $2.86 |
| Resistance Level | $5.71 | $3.15 |
| Average True Range (ATR) | 0.70 | 0.20 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 16.74 | 46.93 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.